Abstract
Response: We thank the authors1 for their thoughtful comments on our article in the May 2010 issue of Stroke regarding the role of erythropoietin (EPO) on oligodendrogenesis after neonatal hypoxic–ischemic (HI) brain injury.2 As mentioned, EPO is neuroprotective against ischemic or HI brain injury in both animal experiments3 and in humans, as evidenced by the recent clinical trial reported.4 Importantly, the cited clinical trial indicated that delayed EPO administration improved long-term outcomes in infants with moderate HI encephalopathy,4 an important consistency with our published treatment paradigm. However, the corresponding mechanism for the long-term functional improvement …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
